These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11426556)

  • 1. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
    Neumeister P; Jaeger G; Eibl M; Sormann S; Zinke W; Linkesch W
    Leuk Lymphoma; 2001 Jan; 40(3-4):345-9. PubMed ID: 11426556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
    List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
    Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
    Ganser A; Maurer A; Contzen C; Seipelt G; Ottmann OG; Schadeck-Gressel C; Kolbe K; Haas R; Zander C; Reutzel R; Hoelzer D
    Ann Hematol; 1996 Apr; 72(4):237-44. PubMed ID: 8624378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
    Bowen DT; Denzlinger C; Brugger W; Culligan D; Gelly K; Adlakha S; Groves M; Hepburn M; Kanz L
    Br J Haematol; 1998 Dec; 103(3):785-7. PubMed ID: 9858231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Erikci AA; Ozturk A; Karagoz B; Bilgi O; Turken O; Top C; Kandemir EG
    Hematology; 2008 Oct; 13(5):289-92. PubMed ID: 18854092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Terzoli E; Amadori S
    Blood; 2002 Mar; 99(5):1578-84. PubMed ID: 11861271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
    Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
    Tefferi A; Elliott MA; Steensma DP; Hook CC; Dispenzieria A; Hanson CA; Schroeder G; Letendre L
    Leuk Res; 2001 Feb; 25(2):183-5. PubMed ID: 11166835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
    Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
    Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
    Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
    Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
    Lu XC; Zhu HL; Yao SQ; Fan H; Zhuang XM; Yang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):440-2. PubMed ID: 15972137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
    Musch E; Malek M; Chrissafidou A
    Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved hematopoiesis using amifostine in secondary myelodysplasia.
    Auletta JJ; Shurin S
    J Pediatr Hematol Oncol; 1999; 21(6):531-4. PubMed ID: 10598667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
    Ganser A; Karthaus M
    Leuk Lymphoma; 1997 Dec; 26 Suppl 1():13-27. PubMed ID: 9570676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.